Stuart Keel1, Jing Xie1, Joshua Foreman1,2, Peter van Wijngaarden1,2, Hugh R Taylor3, Mohamed Dirani1. 1. Centre for Eye Research Australia, Royal Victorian Eye & Ear Hospital, Melbourne, Australia. 2. Department of Surgery, University of Melbourne, Melbourne, Australia. 3. Indigenous Eye Health Unit, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia.
Abstract
Importance: Age-related macular degeneration (AMD) is a leading cause of irreversible blindness among the elderly population globally. Currently, knowledge of the epidemiology of AMD in Australia remains scarce because of a paucity of recent population-based data. Objective: To examine the prevalence of AMD in Australia. Design, Setting, and Participants: In this population-based, cross-sectional survey performed from March 11, 2015, to April 18, 2016, a sample of 3098 nonindigenous Australians 50 years and older and 1738 indigenous Australians 40 years and older from 30 geographic areas across Australia were examined. Main Outcomes and Measures: Any AMD, early AMD, intermediate AMD, and late AMD graded according to the Beckman clinical classification system. Results: A total of 4836 individuals were examined, including 3098 nonindigenous Australian (64.1%; 58.9% female vs 41.1% male; age range, 40-92 years; mean [SD] age, 55.0 [10.0] years) and 1738 indigenous Australians (35.9%; 53.6% female vs 46.4% male; age range, 50-98 years; mean [SD] age, 66.6 [9.7] years). A total of 4589 (94.9%, 2946 nonindigenous and 1643 indigenous) participants had retinal photographs in at least 1 eye that were gradable for AMD. The weighted prevalence of early AMD was 14.8% (95% CI, 11.7%-18.6%) and of intermediate AMD was 10.5% (95% CI, 8.3%-13.1%) among nonindigenous Australians. In indigenous Australians, the weighted prevalence of early AMD was 13.8% (95% CI, 9.7%-19.3%) and of intermediate AMD was 5.7% (96% CI, 4.7%-7.0%). Late AMD was found in 0.96% (95% CI, 0.59%-1.55%) of nonindigenous participants (atrophic, 0.72%; neovascular, 0.24%). The prevalence of late AMD increased to 6.7% in participants 80 years or older and was higher in men (1.4% vs 0.61%, P = .02). Only 3 (0.17% [95% CI, 0.04%-0.63%]) indigenous participants had late (atrophic) AMD. Age-related macular degeneration was attributed as the main cause of vision loss (<6/12 in the better eye) in 23 of 208 nonindigenous Australians (11.1%) and 2 of 183 indigenous Australians (1.1%). Conclusions and Relevance: In line with data from other white populations, AMD is a prominent cause of vision loss in the nonindigenous Australian population. An increased provision of low vision rehabilitation services may be required to cope with the projected increase in AMD in Australia.
Importance: Age-related macular degeneration (AMD) is a leading cause of irreversible blindness among the elderly population globally. Currently, knowledge of the epidemiology of AMD in Australia remains scarce because of a paucity of recent population-based data. Objective: To examine the prevalence of AMD in Australia. Design, Setting, and Participants: In this population-based, cross-sectional survey performed from March 11, 2015, to April 18, 2016, a sample of 3098 nonindigenous Australians 50 years and older and 1738 indigenous Australians 40 years and older from 30 geographic areas across Australia were examined. Main Outcomes and Measures: Any AMD, early AMD, intermediate AMD, and late AMD graded according to the Beckman clinical classification system. Results: A total of 4836 individuals were examined, including 3098 nonindigenous Australian (64.1%; 58.9% female vs 41.1% male; age range, 40-92 years; mean [SD] age, 55.0 [10.0] years) and 1738 indigenous Australians (35.9%; 53.6% female vs 46.4% male; age range, 50-98 years; mean [SD] age, 66.6 [9.7] years). A total of 4589 (94.9%, 2946 nonindigenous and 1643 indigenous) participants had retinal photographs in at least 1 eye that were gradable for AMD. The weighted prevalence of early AMD was 14.8% (95% CI, 11.7%-18.6%) and of intermediate AMD was 10.5% (95% CI, 8.3%-13.1%) among nonindigenous Australians. In indigenous Australians, the weighted prevalence of early AMD was 13.8% (95% CI, 9.7%-19.3%) and of intermediate AMD was 5.7% (96% CI, 4.7%-7.0%). Late AMD was found in 0.96% (95% CI, 0.59%-1.55%) of nonindigenous participants (atrophic, 0.72%; neovascular, 0.24%). The prevalence of late AMD increased to 6.7% in participants 80 years or older and was higher in men (1.4% vs 0.61%, P = .02). Only 3 (0.17% [95% CI, 0.04%-0.63%]) indigenous participants had late (atrophic) AMD. Age-related macular degeneration was attributed as the main cause of vision loss (<6/12 in the better eye) in 23 of 208 nonindigenous Australians (11.1%) and 2 of 183 indigenous Australians (1.1%). Conclusions and Relevance: In line with data from other white populations, AMD is a prominent cause of vision loss in the nonindigenous Australian population. An increased provision of low vision rehabilitation services may be required to cope with the projected increase in AMD in Australia.
Authors: W Smith; J Assink; R Klein; P Mitchell; C C Klaver; B E Klein; A Hofman; S Jensen; J J Wang; P T de Jong Journal: Ophthalmology Date: 2001-04 Impact factor: 12.079
Authors: Ryo Kawasaki; Jie Jin Wang; Tin Aung; Donald T H Tan; Paul Mitchell; Mya Sandar; Seang-Mei Saw; Tien Y Wong Journal: Ophthalmology Date: 2008-04-25 Impact factor: 12.079
Authors: Wan Ling Wong; Xinyi Su; Xiang Li; Chui Ming G Cheung; Ronald Klein; Ching-Yu Cheng; Tien Yin Wong Journal: Lancet Glob Health Date: 2014-01-03 Impact factor: 26.763
Authors: Kehinde Obamiro; Belinda Jessup; Penny Allen; Victoria Baker-Smith; Santosh Khanal; Tony Barnett Journal: Int J Environ Res Public Health Date: 2022-07-14 Impact factor: 4.614
Authors: Silja Hansen; Anne Louise Askou; Morten la Cour; Thomas J Corydon; Toke Bek Journal: Transl Vis Sci Technol Date: 2021-06-01 Impact factor: 3.283
Authors: Adnan H Khan; Janice Sutton; Angela J Cree; Samir Khandhadia; Gabriella De Salvo; John Tobin; Priya Prakash; Rashi Arora; Winfried Amoaku; Peter Charbel Issa; Robert E MacLaren; Paul N Bishop; Tunde Peto; Quresh Mohamed; David H Steel; Sobha Sivaprasad; Clare Bailey; Geeta Menon; David Kavanagh; Andrew J Lotery Journal: Hum Mutat Date: 2021-06-29 Impact factor: 4.700
Authors: Scott A Read; Rebecca A Cox; David Alonso-Caneiro; Shelley Hopkins; Joanne M Wood Journal: Transl Vis Sci Technol Date: 2020-11-20 Impact factor: 3.283
Authors: Liubov D Robman; Le Thi Phuong Thao; Robyn H Guymer; Rory Wolfe; Robyn L Woods; Lauren Ab Hodgson; James Phung; Galina A Makeyeva; Y-Anh Le-Pham; Suzanne G Orchard; Jewhara Suleiman; Emily Maguire; Ruth E Trevaks; Stephanie A Ward; Moeen Riaz; Paul Lacaze; Elsdon Storey; Walter P Abhayaratna; Mark R Nelson; Michael E Ernst; Christopher M Reid; John J McNeil Journal: Contemp Clin Trials Commun Date: 2020-10-11
Authors: Thales Antonio Cabral de Guimaraes; Michalis Georgiou; James W B Bainbridge; Michel Michaelides Journal: Br J Ophthalmol Date: 2020-04-08 Impact factor: 4.638